Literature DB >> 29362167

The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.

Laura J Anderson1, Paul Shekelle2, Emmett Keeler3, Lori Uscher-Pines3, Roberta Shanman3, Sally Morton4, Gursel Aliyev3, Teryl K Nuckols5.   

Abstract

CONTEXT: Influenza vaccination rates remain below Healthy People 2020 goals. This project sought to systematically review economic evaluations of healthcare-based quality improvement interventions for improving influenza vaccination uptake among general populations and healthcare workers. EVIDENCE ACQUISITION: The databases MEDLINE, Econlit, Centre for Reviews & Dissemination, Greylit, and Worldcat were searched in July 2016 for papers published from January 2004 to July 2016. Eligible studies evaluated efforts by bodies within the healthcare system to encourage influenza vaccination by means of an organizational or structural change. For each study, program costs per enrollee and per additional enrollee vaccinated were derived (excluding vaccine costs, standardized to 2017 U.S. dollars). Complete economic evaluations were examined when available. EVIDENCE SYNTHESIS: Of 2,350 records, 18 articles were eligible and described 29 unique interventions. Most interventions improved vaccine uptake. Among 23 interventions in general populations, the median program cost was $3.27 (interquartile range, $0.82-$11.53) per enrollee and $50.78 (interquartile range, $27.85-$124.84) per additional enrollee vaccinated. Among ten complete economic evaluations in general populations, three studies reported net cost savings, four reported costs <$50,000 per quality-adjusted life year, and three reported costs <$60,000 per life saved. Among six interventions in healthcare workers, the median program cost was $8.09 (interquartile range, $5.03-$10.31) per worker enrolled and $125.24 (interquartile range, $96.06-$171.38) per additional worker vaccinated (there were no complete economic analyses).
CONCLUSIONS: Quality improvement interventions for influenza vaccination involve per-enrollee costs that are similar to the cost of the vaccine itself ($11.78-$36.08/dose). Based on limited available evidence in general populations, quality improvement interventions may be cost saving to cost effective for the health system.
Copyright © 2017 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29362167      PMCID: PMC5788040          DOI: 10.1016/j.amepre.2017.11.010

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  4 in total

1.  Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.

Authors:  Andres Chang; Jackelyn B Payne; Pamela B Allen; Jean L Koff; Rafi Ahmed; Christopher R Flowers; Robert A Bednarczyk
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-01-02

2.  Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.

Authors:  Justin Chin; YaQun Zhou; Chijen L Chen; Christine M Lomiguen; Suzanne McClelland; Mary Lee-Wong
Journal:  Cureus       Date:  2021-01-07

3.  Effectiveness of a pay-it-forward intervention compared with user-paid vaccination to improve influenza vaccine uptake and community engagement among children and older adults in China: a quasi-experimental pragmatic trial.

Authors:  Dan Wu; Chenqi Jin; Khaoula Bessame; Fanny Fong-Yi Tang; Jason J Ong; Zaisheng Wang; Yewei Xie; Mark Jit; Heidi J Larson; Tracey Chantler; Leesa Lin; Wenfeng Gong; Fan Yang; Fengshi Jing; Shufang Wei; Weibin Cheng; Yi Zhou; Nina Ren; Shuhao Qiu; Jianmin Bao; Liufen Wen; Qinlu Yang; Junzhang Tian; Weiming Tang; Joseph D Tucker
Journal:  Lancet Infect Dis       Date:  2022-07-19       Impact factor: 71.421

4.  Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey.

Authors:  Andres Chang; Mallory K Ellingson; Christopher R Flowers; Robert A Bednarczyk
Journal:  Open Forum Infect Dis       Date:  2021-04-20       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.